Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
University of Helsinki · GlaxoSmithKline (Belgium) · +22 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,313
total citations
- FWCI
- 106.81
- Percentile
- 100%
- References
- 25
Citations per year
Authors
24Topics & keywords
Topics
Keywords
- Medicine
- Vaccine trial
- Cervical intraepithelial neoplasia
- Cervical cancer
- Vaccine efficacy
- Vaccination
- Interim analysis
- Cohort
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.